Sun Pharma's C S Muralidharan Speaks On The Firm's Q2Fy23 Results & Fy23 Revenue Guidance

Sun Pharma's C S Muralidharan Speaks On The Firm's Q2FY23 Results & FY23 Revenue Guidance

Sun Pharma's CS Muralidharan On Q4 Results, Taro Acquisition Plans & FY24 Outlook | Halftime Report

Sun Pharma's Q3 Net Profit Rises 5% YoY: C.S. Muralidharan Tracks The Firm's Q3FY23 Earnings

JM Financial's Cyndrella Carvalho Shares Her Views On Q2FY23 Results Of Sun Pharma | CNBC-TV18

C.S. Muralidharan Of Sun Pharma Speaks On Q3 Performance, New Launches & More | Business News

Growth Witnessed Across Most Therapies | C S Muralidharan, Sun Pharmaceutical Industries

Sun Pharma Healthy Q2 Results: PAT, Margin Beat Estimates, Cuts R&D Guidance & U.S Business Check

Sun Pharma's Buyout Plans & Q4 Numbers | CS Muralidharan Explains | Business News

Sun Pharma Margins Trend To Sustain In Coming Quarters? | CS Muralidharan Explains | ET Now

Max Healthcare's Abhay Soi Speaks On The Firm's Q2FY23 Results | Bazaar Open Exchange | CNBC-TV18

Sun Pharma Q4: What Are The Key Growth Drivers Aiding India & U.S Business? | CS Muralidharan

UPL Management Exclusive On The Firm's Q2FY23 Results | Chartbusters | CNBC-TV18

Vishnu Chemicals' Siddartha Cherukuri Exclusive On The Firm's Q2FY23 Earnings | Midcap Radar

Macrotech Developers' Sushil Kumar Modi Speaks On The Firm's Q2FY23 Results | Bazaar Open Exchange

Sun Pharma To Report Its Q2 Results Today, Here Is What Expect | Trading Hour | CNBC-TV18

Sun Pharma Q3 Earnings Fineprint | 11% Pick Up In India Formulation Sales | CS Muralidharan Explains

Sun Pharma Q4: Revenue At ₹11,983 Cr, Misses Est, Net Profit Above Est At ₹2,654.5 Cr | CNBC TV18

Award for Sectoral Performance based category-Pharmaceuticals- Sun Pharmaceutical Industries Limited

Dun & Bradstreet India

3 Silver, Gold, Copper & Zinc Projects in Arizona | Intrepid Metals CEO Interview

Sun Pharma Q2; Price Hikes And Factors Aiding India Business Growth | CS Muralidharan